Autoimmune pleural effusion is a medical complication characterized by the excessive presence of fluid in the space located between the lungs and the chest wall. In an optimal state of health, the pleural space contains only a few milliliters of fluid that serve as a lubricant for respiratory movement. However, this balance is broken when systemic diseases cause the immune system to attack its own tissues. This pathology commonly originates in patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis, where the inflammation of serous membranes generates an anomalous exudate. Therefore, the fluid accumulates progressively, compressing the underlying lung tissue and limiting the expansion of the chest. Consequently, the physical result is a significant decrease in respiratory capacity.
Moreover, the abnormal accumulation of fluid responds to a process of chronic inflammation of the pleura that alters the permeability of local blood vessels. It is important to highlight that autoimmune pleural effusion usually presents as an exudate rich in proteins and inflammatory cells. Nevertheless, the speed at which the fluid accumulates determines the severity of the immediate clinical symptoms. As a result, the patient experiences dyspnea or shortness of breath, as the affected lung cannot fill with oxygen efficiently. The associated chest pain is typically pleuritic in nature, sharpening with each deep inspiration or coughing attempt. Furthermore, the presence of this fluid can lead to long-term lung restrictions.
For this reason, identifying the specific autoimmune cause requires a detailed analysis of the fluid through a procedure known as thoracentesis. In view of this, extracting a sample allows for differentiating this effusion from others caused by heart failure or bacterial infections. Due to this condition, glucose levels, pH, and the presence of specific antibodies in the pleural fluid are key diagnostic indicators. On the other hand, primary management focuses on controlling the underlying disease through the use of potent immunosuppressants and corticosteroids. Accordingly, dyspnea usually improves significantly once the excess fluid is removed and the aggressive immune response is reduced.
Finally, the comprehensive management of autoimmune pleural effusion seeks to prevent the formation of adhesions or fibrosis that could permanently restrict lung function. Although pharmacological treatment is the foundation, therapeutic drainage is required in some cases to immediately relieve intrathoracic pressure. In summary, joint rheumatological and pulmonological follow-up is essential to monitor fluid recurrence. Ultimately, the main goal is to normalize the volume of the pleural space and protect the integrity of the lung parenchyma against the inflammatory attack. Lastly, the patient’s stability depends on strict adherence to immune system-modulating therapy.